MBX · MBX Biosciences Inc
United States · RS rating 68 · As of 2026-11-03
| Price | 55.00 USD |
|---|---|
| 1-day change | +1.1% |
| RS rating (overall / 1M / 3M / 12M) | 68 / 43 / 33 / 96 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 37 / 36 / 28 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +22.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +22.2% |
| Market cap (USD) | $1.6B |